<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716610</url>
  </required_header>
  <id_info>
    <org_study_id>Samba-02</org_study_id>
    <nct_id>NCT02716610</nct_id>
  </id_info>
  <brief_title>Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes</brief_title>
  <acronym>Samba-02</acronym>
  <official_title>Samba-02: An Investigation of the Dose-Response and Subject Variability of Inhaled Insulin in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dance Biopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dance Biopharm Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetic (PK) and Pharmacodynamic (PD) dose-response investigation of Dance-501
      inhaled human insulin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigated the pharmacokinetic (PK) and pharmacodynamic (PD) properties of
      Dance-501, a novel inhaled human insulin liquid formulation (INH) and device. Twenty-four
      subjects with type 2 diabetes (T2DM) received 3 INH doses: low (69 units), medium (139 units)
      and high (208 units) and 1 equivalent medium dose (18 units) of subcutaneous insulin lispro
      (LIS).

      The medium dose was repeated to determine within subject variability. PD was investigated
      during a 12 hour euglycemic clamp.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve for insulin from 0-8 hours (AUCins0-8h)</measure>
    <time_frame>0 to 8 hours following each dose</time_frame>
    <description>Assessment of the linearity of the dose-response curves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of insulin (CMaxIns)</measure>
    <time_frame>up to 12 hours following each dose</time_frame>
    <description>Assessment of the linearity of the dose-response curves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve for glucose infusion rate from 0-12 hours (AUGgir0-12h)</measure>
    <time_frame>0 to 8 hours following each dose</time_frame>
    <description>Assessment of the linearity of the dose-response curves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum glucose infusion rate (GIRmax)</measure>
    <time_frame>up to 12 hours following each dose</time_frame>
    <description>Assessment of the linearity of the dose-response curves</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>0 to 8 hours following each dose</time_frame>
    <description>Relative delivery efficiency (FREL) of inhaled human insulin (INH) compared to subcutaneous injected insulin lispro (LIS)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>INH 69 U (low)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INH 69 U (high)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INH 139 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INH 208 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIS 18 U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INH 69 U (low)</intervention_name>
    <description>inhaled human insulin</description>
    <arm_group_label>INH 69 U (low)</arm_group_label>
    <other_name>Dance-501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INH 69 U (high)</intervention_name>
    <description>inhaled human insulin</description>
    <arm_group_label>INH 69 U (high)</arm_group_label>
    <other_name>Dance-501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INH 139 U</intervention_name>
    <description>inhaled human insulin</description>
    <arm_group_label>INH 139 U</arm_group_label>
    <other_name>Dance-501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INH 208 U</intervention_name>
    <description>inhaled human insulin</description>
    <arm_group_label>INH 208 U</arm_group_label>
    <other_name>Dance-501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIS 18 U</intervention_name>
    <description>subcutaneous insulin lispro</description>
    <arm_group_label>LIS 18 U</arm_group_label>
    <other_name>subcutaneous insulin lispro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus treated with insulin injections at a total daily dose less
             than 1.2 U/kg/day.

          -  Body mass index 25-40 kg/m2

          -  Hemoglobin A1c 6.5-9.5%

          -  Forced vital capacity and forced expiratory volume in 1 second at least 75% of
             predicted normal values.

          -  Fasting c-peptide less than 1 nmol/L

        Exclusion Criteria:

          -  Any condition possibly affecting drug absorption from the lung, in particular subjects
             with decreased lung function or subjects taking bronchodilators or subjects who smoke.

          -  Active or chronic pulmonary disease.

          -  Any major disorder other than type 2 diabetes.

          -  Decompensated heart failure or myocardial infarction at any time or angina pectoris
             within the last 12 months.

          -  Proliferative retinopathy or maculopathy or severe neuropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Heise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut fuÌˆr Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

